$ARRY Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARRAY BIOPHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARRAY BIOPHARMA INC. Get notifications about new insider transactions in ARRAY BIOPHARMA INC for free.
Page: < prev 1 2 3 4 5 6 ... 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 11,100 | 99,234 | 403,900 | |
| Jan 29 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 14,029 | 125,419 | 415,000 | |
| Jan 29 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Sell | S | 18.00 | 14,029 | 252,523 | 3,921 | 18 K to 3.9 K (-78.16 %) |
| Jan 29 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 14,029 | 125,419 | 17,950 | 3.9 K to 18 K (+357.79 %) |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 1,251 | 11,184 | 429,029 | |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 1,251 | 11,184 | 429,029 | |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Sell | S | 18.00 | 1,251 | 22,518 | 3,921 | 5.2 K to 3.9 K (-24.19 %) |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Sell | S | 18.00 | 1,251 | 22,518 | 3,921 | 5.2 K to 3.9 K (-24.19 %) |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 1,251 | 11,184 | 5,172 | 3.9 K to 5.2 K (+31.91 %) |
| Jan 23 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 1,251 | 11,184 | 5,172 | 3.9 K to 5.2 K (+31.91 %) |
| Jan 17 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 19,720 | 176,297 | 430,280 | |
| Jan 17 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Sell | S | 18.06 | 19,720 | 356,139 | 3,921 | 23.6 K to 3.9 K (-83.41 %) |
| Jan 17 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 19,720 | 176,297 | 23,641 | 3.9 K to 23.6 K (+502.93 %) |
| Jan 02 2019 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 14.05 | 6,268 | 88,091 | 228,998 | 235.3 K to 229 K (-2.66 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 12,062 | 0 | 36,188 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 11,284 | 0 | 22,570 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 15.97 | 289,500 | 4,623,315 | 289,500 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 0.00 | 48,250 | 0 | 48,250 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 15.97 | 10,378 | 165,737 | 235,266 | 245.6 K to 235.3 K (-4.22 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 0.00 | 23,346 | 0 | 245,644 | 222.3 K to 245.6 K (+10.50 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 7,000 | 0 | 21,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 5,469 | 0 | 10,938 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 15.97 | 138,000 | 2,203,860 | 138,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 0.00 | 23,000 | 0 | 23,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 15.97 | 5,485 | 87,595 | 68,677 | 74.2 K to 68.7 K (-7.40 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 0.00 | 12,469 | 0 | 74,162 | 61.7 K to 74.2 K (+20.21 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,968 | 0 | 41,907 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,083 | 0 | 26,166 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 15.97 | 315,750 | 5,042,528 | 315,750 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 52,625 | 0 | 52,625 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 15.97 | 11,898 | 190,011 | 174,620 | 186.5 K to 174.6 K (-6.38 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 27,051 | 0 | 186,518 | 159.5 K to 186.5 K (+16.96 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 0.00 | 7,000 | 0 | 21,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | A | 15.97 | 116,250 | 1,856,513 | 116,250 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | A | 0.00 | 19,375 | 0 | 19,375 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Payment of Exercise | F | 15.97 | 3,079 | 49,172 | 3,921 | 7 K to 3.9 K (-43.99 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 0.00 | 7,000 | 0 | 7,000 | 0 to 7 K |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 25,000 | 0 | 75,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 23,437 | 0 | 46,876 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 678,750 | 0 | 678,750 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 113,125 | 0 | 113,125 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 15.97 | 21,303 | 340,209 | 238,709 | 260 K to 238.7 K (-8.19 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 48,437 | 0 | 260,012 | 211.6 K to 260 K (+22.89 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 0.00 | 7,000 | 0 | 21,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 0.00 | 4,387 | 0 | 8,766 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 15.97 | 157,500 | 2,515,275 | 157,500 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 0.00 | 26,250 | 0 | 26,250 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Payment of Exercise | F | 15.97 | 5,009 | 79,994 | 41,771 | 46.8 K to 41.8 K (-10.71 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 0.00 | 11,387 | 0 | 46,780 | 35.4 K to 46.8 K (+32.17 %) |
| Dec 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 3.65 | 127,397 | 464,999 | 151,862 | |
| Dec 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 16.21 | 115,185 | 1,867,045 | 222,298 | 337.5 K to 222.3 K (-34.13 %) |
| Dec 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 3.65 | 127,397 | 464,999 | 337,483 | 210.1 K to 337.5 K (+60.64 %) |
| Nov 05 2018 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Buy | P | 16.87 | 3,000 | 50,595 | 3,000 | 0 to 3 K | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 0.00 | 5,000 | 0 | 24,297 | 19.3 K to 24.3 K (+25.91 %) | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Buy | M | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 0.00 | 5,000 | 0 | 22,720 | 17.7 K to 22.7 K (+28.22 %) | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Buy | M | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) | |
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 14.55 | 25,000 | 363,750 | 25,000 | ||
| Oct 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) | |
| Sep 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.95 | 18,000 | 107,100 | 0 | ||
| Sep 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 14.76 | 18,000 | 265,684 | 19,297 | 37.3 K to 19.3 K (-48.26 %) | |
| Sep 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.95 | 18,000 | 107,100 | 37,297 | 19.3 K to 37.3 K (+93.28 %) | |
| Sep 05 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 15.38 | 9,687 | 148,938 | 210,086 | 219.8 K to 210.1 K (-4.41 %) |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | A | 8.94 | 450,000 | 4,023,000 | 450,000 | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Director | Option Exercise | A | 14.93 | 25,000 | 373,250 | 25,000 | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 13.92 | 20,000 | 278,400 | 35,393 | 55.4 K to 35.4 K (-36.11 %) |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 13.92 | 20,000 | 278,400 | 35,393 | 55.4 K to 35.4 K (-36.11 %) |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.60 | 14,500 | 81,200 | 0 | ||
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.60 | 14,500 | 81,200 | 0 | ||
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.95 | 7,000 | 41,650 | 18,000 | ||
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.95 | 7,000 | 41,650 | 18,000 | ||
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 13.92 | 21,500 | 299,280 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 13.92 | 21,500 | 299,280 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.60 | 14,500 | 81,200 | 40,797 | 26.3 K to 40.8 K (+55.14 %) | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.60 | 14,500 | 81,200 | 40,797 | 26.3 K to 40.8 K (+55.14 %) | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.95 | 7,000 | 41,650 | 26,297 | 19.3 K to 26.3 K (+36.28 %) | |
| Aug 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.95 | 7,000 | 41,650 | 26,297 | 19.3 K to 26.3 K (+36.28 %) | |
| Jul 31 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 3.77 | 51,525 | 194,249 | 489,450 | |
| Jul 31 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 14.87 | 25,000 | 371,750 | 55,393 | 80.4 K to 55.4 K (-31.10 %) |
| Jul 31 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 3.77 | 51,525 | 194,249 | 80,393 | 28.9 K to 80.4 K (+178.48 %) |
| Jul 19 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.13 | 11,000 | 56,430 | 0 | ||
| Jul 19 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.60 | 10,500 | 58,800 | 14,500 | ||
| Jul 19 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 16.56 | 21,500 | 356,040 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Jul 19 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.13 | 11,000 | 56,430 | 40,797 | 29.8 K to 40.8 K (+36.92 %) | |
| Jul 19 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.60 | 10,500 | 58,800 | 29,797 | 19.3 K to 29.8 K (+54.41 %) | |
| Jul 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 5.95 | 25,000 | 148,750 | 0 | |
| Jul 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 5.13 | 25,000 | 128,250 | 0 | |
| Jul 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Sell | S | 17.45 | 50,000 | 872,500 | 17,720 | 67.7 K to 17.7 K (-73.83 %) |
| Jul 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 5.95 | 25,000 | 148,750 | 67,720 | 42.7 K to 67.7 K (+58.52 %) |
| Jul 06 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 5.13 | 25,000 | 128,250 | 42,720 | 17.7 K to 42.7 K (+141.08 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 11,453 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 18.50 | 5,038 | 93,203 | 61,693 | 66.7 K to 61.7 K (-7.55 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 0.00 | 11,453 | 0 | 66,731 | 55.3 K to 66.7 K (+20.72 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 32,068 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 17.74 | 17,964 | 318,681 | 159,467 | 177.4 K to 159.5 K (-10.12 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 18.50 | 14,104 | 260,924 | 177,431 | 191.5 K to 177.4 K (-7.36 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 32,068 | 0 | 191,535 | 159.5 K to 191.5 K (+20.11 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 8.79 | 140,625 | 1,236,094 | 421,875 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 77,881 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.03 | 140,625 | 2,535,469 | 211,575 | 352.2 K to 211.6 K (-39.93 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 8.79 | 140,625 | 1,236,094 | 352,200 | 211.6 K to 352.2 K (+66.47 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 17.74 | 43,628 | 773,961 | 211,575 | 255.2 K to 211.6 K (-17.10 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 18.50 | 34,253 | 633,681 | 255,203 | 289.5 K to 255.2 K (-11.83 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 77,881 | 0 | 289,456 | 211.6 K to 289.5 K (+36.81 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 17,440 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 18.50 | 7,753 | 143,431 | 219,773 | 227.5 K to 219.8 K (-3.41 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 0.00 | 17,440 | 0 | 227,526 | 210.1 K to 227.5 K (+8.30 %) |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 4.36 | 7,500 | 32,700 | 0 | ||
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 5.13 | 14,000 | 71,820 | 11,000 | ||
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 19.08 | 21,500 | 410,220 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.13 | 14,000 | 71,820 | 40,797 | 26.8 K to 40.8 K (+52.24 %) | |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 4.36 | 7,500 | 32,700 | 26,797 | 19.3 K to 26.8 K (+38.87 %) | |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 3.65 | 77,576 | 283,152 | 279,259 | |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 18.76 | 77,576 | 1,455,326 | 210,086 | 287.7 K to 210.1 K (-26.97 %) |
| Jun 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 3.65 | 77,576 | 283,152 | 287,662 | 210.1 K to 287.7 K (+36.93 %) |
| Jun 15 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 3.65 | 22,424 | 81,848 | 356,835 | |
| Jun 15 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 18.75 | 22,424 | 420,450 | 210,086 | 232.5 K to 210.1 K (-9.64 %) |
| Jun 15 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 3.65 | 22,424 | 81,848 | 232,510 | 210.1 K to 232.5 K (+10.67 %) |
| May 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Option Exercise | M | 3.87 | 9,000 | 34,830 | 0 | |
| May 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Option Exercise | M | 4.36 | 12,500 | 54,500 | 7,500 | |
| May 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Sell | S | 15.36 | 21,500 | 330,259 | 19,297 | 40.8 K to 19.3 K (-52.70 %) |
| May 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Buy | M | 3.87 | 9,000 | 34,830 | 40,797 | 31.8 K to 40.8 K (+28.30 %) |
| May 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Buy | M | 4.36 | 12,500 | 54,500 | 31,797 | 19.3 K to 31.8 K (+64.78 %) |
| Apr 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.87 | 16,000 | 61,920 | 9,000 | ||
| Apr 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.51 | 5,500 | 19,305 | 0 | ||
| Apr 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 15.19 | 21,500 | 326,585 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Apr 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.87 | 16,000 | 61,920 | 40,797 | 24.8 K to 40.8 K (+64.52 %) | |
| Apr 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.51 | 5,500 | 19,305 | 24,797 | 19.3 K to 24.8 K (+28.50 %) | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 7,812 | 0 | 15,626 |